Nature Genetics - A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation Skip to main content Thank you for visiting nature.com.

After IL-1 binds to the type I receptor, it will couple with the IL-1 accessory protein and form a heterodimer that leads to transmembrane signaling (Figure 13-1).

Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients ...

The first direct and selective interleukin-1 (IL-1) receptor antagonist, ... Cite this: Interleukin-1 Blocker for Rheumatoid Arthritis - Medscape - Jan 01, 2002.

The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron ...

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and ...

There were associations for GLP-1 RA treatment versus placebo with improvements in restrained eating and emotional eating behavior (Hedges g = 0.35 and 0.32) and in mental health-related QOL ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community needs to figure out how to keep patients on the drugs long term to fully ...